Analysis of the efficacy and safety of Bestifan (Viliru) in clinical studies of renal cancer

Belzutifan (Belzutifan) is an oral small molecule HIF-2α inhibitor, mainly used to treat patients with renal cell carcinoma associated with VHL gene mutations. Its mechanism of action is to selectively inhibit HIF-2α transcriptional activity and block the hypoxic adaptation signal of tumor cells, thereby inhibiting tumor angiogenesis and tumor growth. This targeting effect provides new treatment options for patients with refractory or relapsed kidney cancer, especially those who are resistant to traditional targeted drugs or immunotherapy.

In clinical studies, bestivan has shown significant efficacy. Research data shows that among patients with advanced renal cancer treated with bezotevan, the overall response rate (ORR) can reach approximately 25% to 30%, and some patients even achieve complete response (CR). In addition, the median progression-free survival (PFS) was significantly prolonged, suggesting that bezotivan can effectively delay disease progression. These results show that besetifan has stable anti-tumor activity in patients with VHL-related renal cancer, providing a reliable basis for clinical treatment.

The safety of bestivan is generally controllable, and common adverse reactions include anemia, fatigue, headache, and nausea. Most adverse reactions are mild to moderate and can be relieved by supportive treatment or dose adjustment. A small number of patients may develop severe anemia or abnormal liver function, requiring close monitoring of blood routine and liver and kidney function. In clinical use, doctors will formulate individualized medication plans based on the patient's specific conditions to maximize the efficacy while reducing risks.

To sum up, bezotivan shows high clinical value in the treatment of renal cancer. Its mechanism of action by specifically targeting HIF-2α provides a new treatment approach for renal cancer patients, which can not only effectively prolong progression-free survival but also have controllable safety. Clinically, through reasonable monitoring and dose adjustment, the efficacy can be maximized, while providing an important reference for further research and combination treatment in the future.

Reference materials:https://www.drugs.com/